Long Châu, AstraZeneca Launch New Asthma Therapy in Vietnam
Why this is here: Long Châu’s network of 2,500 pharmacies will make the new therapy accessible to patients in 34 Vietnamese provinces, functioning as a key initial point of healthcare access.
Long Châu and AstraZeneca have begun offering a new asthma therapy in Vietnam. The treatment uses the active ingredient Tezepelumab, targeting a protein linked to asthma and allergies. Clinical studies show Tezepelumab may reduce asthma attacks and improve respiratory function.
The U.S. Food and Drug Administration approved Tezepelumab for adults and children age 12 and older with severe asthma. Long Châu will distribute the therapy through its network of nearly 2,500 pharmacies across 34 provinces.
Long Châu pharmacists will provide consultation and information. AstraZeneca stated this launch supports its global efforts to improve health for those with severe asthma. The collaboration aims to raise healthcare standards in Vietnam and manage chronic diseases.